Abstract 82P
Background
Neoadjuvant immunochemotherapy (NICT) has been shown to effectively increase the proportion of pathologic complete response (pCR) in locally advanced HNSCC, driver-gene-negative NSCLC, and esophageal squamous cell carcinoma. Nonetheless, accurately predicting which patients will benefit most from this treatment strategy remains a significant challenge.
Methods
This retrospective analysis includes 485 patients with locally advanced cancer who were treated with NICT at our center from January 2020 to January 2024. Based on pre- and post-neoadjuvant treatment imaging data, patients were divided into groups according to tumor shrinkage: greater than 50%, 30% to 50%, and less than 30%. The study also examined PD-L1 expression levels and changes in lymphocyte counts pre and post treatment , to analyze their correlation with pCR rates.
Results
ESCC (147 cases): The pCR rate was 25% among patients with tumor shrinkage over 50%, significantly higher than that in patients with shrinkage less than 30% (pCR rate 4.2%). The pCR rate in the group with an increase in lymphocyte count (14.1%) was significantly higher than in the group with a decrease (6.9%).NSCLC (176 cases): Primarily treated with a PC regimen consisting of carboplatin and paclitaxel. The pCR rate was 57.8% in patients with more than 50% tumor shrinkage, significantly higher compared to those with less than 30% shrinkage (pCR rate 4.8%). The group with increased lymphocyte counts (41.5%) had a better pCR rate than the decreased group (30.1%). HNSCC (162 cases): Patients with over 50% tumor shrinkage had a pCR rate of 69.8%, compared to 21.1% in those with less than 30% shrinkage. The pCR rate in the lymphocyte increased group (47.8%) was slightly lower than in the decreased group (59.0%). Additionally, initial CPS and TPS scores did not show significant correlation with pCR across the three types of cancer.
Conclusions
Tumor shrinkage rates and changes in lymphocyte counts are effective predictive biomarkers for the efficacy of NICT. Significant tumor shrinkage and increased lymphocyte numbers correlate with higher pCR rates, helping to identify patients who may benefit from NICT.
Legal entity responsible for the study
Zhanjie Zhang.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
76P - Fixed 2-year vs. continuous duration immune checkpoint inhibitors in patients diagnosed with advanced cancer: to continue or not to continue?
Presenter: Miles Smith
Session: Poster Display session
Resources:
Abstract
77P - A new prognostic index for patients with advanced BTC treated with cisplatin, gemcitabine and durvalumab
Presenter: MARA PERSANO
Session: Poster Display session
Resources:
Abstract
79P - Relevance of combined positive score (CPS) & low-dose immune checkpoint inhibitors (ICIs) in microsatellite stable (MSS) advanced gastric adenocarcinoma (GC): A multi-institution analysis
Presenter: Anant Ramaswamy
Session: Poster Display session
Resources:
Abstract
80P - Tumor markers evolution in pts treated with TCE and association with radiologic response
Presenter: Constance d'Abrigeon
Session: Poster Display session
Resources:
Abstract
81P - Predictive value of inflammatory ratios on the outcome of advanced melanoma patients treated with anti-PD1 monotherapy: A multicentric analysis
Presenter: Aleksandar Popovic
Session: Poster Display session
Resources:
Abstract
83P - Effectiveness and safety of neoadjuvant immunochemotherapy with and without surgery in patients with resectable esophageal squamous cell carcinoma: A retrospective cohort study
Presenter: xuqiang liao
Session: Poster Display session
Resources:
Abstract
84P - Safety Of Treatment With Immune Checkpoint Inhibitors In Older Adults With Non-Small Cell Lung Cancer
Presenter: Verene Dougoud-Chauvin
Session: Poster Display session
Resources:
Abstract
86P - Treatment trajectories and outcome following irAE related hospitalization in metastatic cancer patients
Presenter: Veera Nurmela
Session: Poster Display session
Resources:
Abstract
87P - Access to vedolizumab for the management of immune-related colitis (IRC): A United Kingdom study
Presenter: Faye Coe
Session: Poster Display session
Resources:
Abstract
88P - Utilisation of the ESMO-MCBS in prioritising immune-checkpoint inhibitors for a WHO model list of essential medicines application
Presenter: Mario Csenar
Session: Poster Display session
Resources:
Abstract